VanEck Associates
ACAD icon

VanEck Associates’s Acadia Pharmaceuticals ACAD Stock Holding History

VanEck Associates’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-200,190
Closed -$6.03M – 745
2017
Q4 		$6.03M Sell
200,190
-100,054
-33% -$3.2M 0.03% 271
2017
Q3 		$11.3M Buy
300,244
+32,470
+12% +$1.06M 0.06% 232
2017
Q2 		$7.47M Buy
267,774
+54,202
+25% +$1.62M 0.04% 246
2017
Q1 		$7.34M Buy
213,572
+6,130
+3% +$216K 0.03% 261
2016
Q4 		$5.98M Sell
207,442
-589,079
-74% -$15.6M 0.03% 269
2016
Q3 		$25.3M Buy
+796,521
New +$27M 0.12% 115

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

VanEck Associates's ACAD Position: Q1 2018 in Review

VanEck Associates sold out of Acadia Pharmaceuticals (ACAD) in Q1 2018, closing a stake of 200,190 shares — an estimated $6.03M sold.

VanEck Associates first reported a position in ACAD in Q3 2016 and held it in 6 quarters. The position peaked at $25.3M in Q3 2016. 196 funds tracked by Wall St. Rank hold ACAD as of Q1 2018.

  • VanEck Associates reported no remaining Acadia Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • VanEck Associates sold 200,190 Acadia Pharmaceuticals shares in Q1 2018, an estimated $6.03M.
  • VanEck Associates first reported a position in Acadia Pharmaceuticals in Q3 2016 and held it in 6 quarters.
  • VanEck Associates's Acadia Pharmaceuticals position peaked at $25.3M in Q3 2016.
  • 196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2018.

Based on VanEck Associates's 13F filing for Q1 2018, filed 11 May 2018.